| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Gliadin Antibodies (IgA and IgG)
MessageSendout, Mayo test code: DGLDN
Test Code
LAB725
Alias/See Also
Celiac Disease
Coeliac Disease
Gliadin Antibodies IgG and IgA
DGLDN
Coeliac Disease
Gliadin Antibodies IgG and IgA
DGLDN
CPT Codes
86258x2
Preferred Specimen
0.5 mL serum from a gold serum gel tube
Minimum Volume
0.4 mL
Other Acceptable Specimens
Red tube
Instructions
Centrifuge and aliquot serum into a plastic vial.
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 21 days
Frozen: 21 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis: Mild OK; Gross reject
Lipemia: Mild OK; Gross reject
Icterus: Mild OK; Gross OK
Lipemia: Mild OK; Gross reject
Icterus: Mild OK; Gross OK
Methodology
Enzyme-Linked Immunosorbent Assay (ELISA)
FDA Status
Approved
Setup Schedule
Monday, Wednesday, Friday
Report Available
2-4 days
Limitations
This test should not be solely relied upon to establish a diagnosis of celiac disease. It should be used to identify patients who have an increased probability of having celiac disease and in whom a small intestinal biopsy is recommended.
Affected individuals who have been on a gluten-free diet prior to testing may have a negative result.
For individuals who test negative, IgA deficiency should be considered. If total IgA is normal and deamidated gliadin IgA is negative, there is a low probability of the patient having celiac disease and a biopsy may not be necessary.
If serology is negative or there is substantial clinical doubt remaining, then further investigation should be performed with endoscopy and bowel biopsy. This is especially important in patients with frank malabsorptive symptoms since many syndromes can mimic celiac disease. For the patient with frank malabsorptive symptoms, a bowel biopsy should be performed regardless of serologic test results.
Testing for IgA and IgG antibodies to unmodified gliadin proteins is no longer recommended because of the low sensitivity and specificity of these tests for celiac disease.
This test should not be ordered as a replacement for TSTGP / Tissue Transglutaminase Antibodies, IgA and IgG Profile, Serum.
Affected individuals who have been on a gluten-free diet prior to testing may have a negative result.
For individuals who test negative, IgA deficiency should be considered. If total IgA is normal and deamidated gliadin IgA is negative, there is a low probability of the patient having celiac disease and a biopsy may not be necessary.
If serology is negative or there is substantial clinical doubt remaining, then further investigation should be performed with endoscopy and bowel biopsy. This is especially important in patients with frank malabsorptive symptoms since many syndromes can mimic celiac disease. For the patient with frank malabsorptive symptoms, a bowel biopsy should be performed regardless of serologic test results.
Testing for IgA and IgG antibodies to unmodified gliadin proteins is no longer recommended because of the low sensitivity and specificity of these tests for celiac disease.
This test should not be ordered as a replacement for TSTGP / Tissue Transglutaminase Antibodies, IgA and IgG Profile, Serum.
Reference Range
Included with report
Clinical Significance
Assessment of deaminated gliadin IgA and IgG antibodies for evaluating patients suspected of having celiac disease, including patients with compatible clinical symptoms, patients with atypical symptoms, and individuals at increased risk (family history, previous diagnosis with associated disorder, positivity for HLA DQ2 and/or DQ8).
Monitoring response to a gluten-free diet in patients with celiac disease.
Monitoring response to a gluten-free diet in patients with celiac disease.
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Gliadin (Deamidated) Antibodies Evaluation, IgG and IgA, Serum
